# Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

> **NCT05617664** · NA · UNKNOWN · sponsor: **Benha University** · enrollment: 150 (estimated)

## Conditions studied

- Nocturnal Enuresis

## Interventions

- **DRUG:** desmopressin 120 mcg oral tablets
- **DRUG:** Mirabegron 25 MG Oral Tablet, Extended Release
- **BEHAVIORAL:** behavioral therapy alone

## Key facts

- **NCT ID:** NCT05617664
- **Lead sponsor:** Benha University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-23
- **Primary completion:** 2023-09
- **Final completion:** 2023-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617664, "Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05617664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*